Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Chubb
Johnson and Johnson
Express Scripts
Baxter
Cantor Fitzgerald

Generated: September 16, 2019

DrugPatentWatch Database Preview

Details for Patent: 9,744,209

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Which drugs does patent 9,744,209 protect, and when does it expire?

Patent 9,744,209 protects VASOSTRICT and is included in one NDA.

Summary for Patent: 9,744,209
Title:Vasopressin formulations for use in treatment of hypotension
Abstract: Provided herein are peptide formulations comprising polymers as stabilizing agents. The peptide formulations can be more stable for prolonged periods of time at temperatures higher than room temperature when formulated with the polymers. The polymers used in the present invention can decrease the degradation of the constituent peptides of the peptide formulations.
Inventor(s): Kenney; Matthew (New Haven, MI), Kannan; Vinayagam (Rochester, MI), Vandse; Sunil (Basking Ridge, NJ), Sanghvi; Suketu (Kendall Park, NJ)
Assignee: PAR PHARMACEUTICAL, INC. (Chestnut Ridge, NY)
Application Number:15/426,693
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,744,209
Patent Claim Types:
see list of patent claims
Use; Formulation; Device; Dosage form;

Drugs Protected by US Patent 9,744,209

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Par Sterile Products VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485-001 Apr 17, 2014 RX Yes Yes   Try a Free Trial   Try a Free Trial TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES   Try a Free Trial
Par Sterile Products VASOSTRICT vasopressin SOLUTION;INTRAVENOUS 204485-002 Dec 17, 2016 RX Yes Yes   Try a Free Trial   Try a Free Trial TO INCREASE BLOOD PRESSURE IN ADULTS WITH VASODILATORY SHOCK (E.G., POST-CARDIOTOMY OR SEPSIS) WHO REMAIN HYPOTENSIVE DESPITE FLUIDS AND CATECHOLAMINES   Try a Free Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Queensland Health
Accenture
Harvard Business School
US Department of Justice
Cantor Fitzgerald

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.